

Date: 5th February, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

Press Release

Net Profit up 48% to Rs 180 Crores in Q3

11 Launches in the US market

Vadodara, February 5th, 2024

Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter and nine months period ended 31st December, 2023.

Financial Highlights

- Net Sales grew 8% to Rs.1631 Crores for the quarter.
- Net Profit up 48% to Rs.180 Crores from Rs.122 Crores
- EBITDA up 14% to Rs. 269 Crores.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “The India Branded Business was underpinned by a continued incremental improvement in core operations. The Specialty and Animal health segments continued its strong outperformance; whereas the Acute performance was relatively satisfactory despite challenging market conditions. The Ex US generics grew 32% in the quarter, whereas the US returned to a 9% growth on the back of 11 launches and 7 approvals.”

Operational Highlights

India Branded Business

- India Branded Business at Rs. 596 Crores witnessed growth of 9% for the quarter.
- Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology therapies outpaced market growth.
- Relative degree of performance continue to be better than the market in Antibiotic and Respiratory segments on high base of previous year.
- Animal Health business recorded growth of 32% YoY basis. Basket of strong brands continue to drive outperformance.

International Business

- US Generics grew 9% to Rs. 474 Crores for the quarter.
- Ex-US International Formulations grew 32% to Rs. 272 Crores for the quarter.
- 7 ANDA approvals received during the quarter; 196 Cumulative ANDA approvals.

ALEMBIC PHARMACEUTICALS LIMITED

API Business

- API business at Rs. 289 Crores for the quarter.

The summary of Total Revenue is as under:

(Rs. in Crores)

Particulars	Q3 FY24	Q3 FY23	% Change	9M FY24	9M FY23	% Change
Formulation						
India	596	545	9%	1697	1573	8%
USA	474	432	9%	1308	1218	7%
Ex- US	272	206	32%	790	602	31%
API	289	326	(11%)	916	853	7%
Total	1631	1509	8%	4712	4246	11%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 022- 66953681	Phone: +91 265 – 6637630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123